January 16, 2025
Celadon sees results of collaboration with Valeos
Celadon Pharmaceuticals announced Thursday collaboration with Valeos, a Danish pharmaceutical company, is active and it’s bringing results.
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
January 16, 2025
InflaRx gets EC’s approval for Gohibic for SARS-CoV-2-Induced ARDS
InflaRx N.V. announced Thursday that the European Commission (EC) has granted marketing authorization under exceptional circumstances for GOHIBIC® (vilobelimab) for the treatment of adult patients with SARS-CoV-2-induced acute respiratory distress syndrome
January 16, 2025
Idorsia Pharmaceuticals, R-Bridge Healthcare Fund in royalty monetization agreement for Agamree
Santhera Pharmaceuticals said Thursday that Idorsia Pharmaceuticals has entered into a royalty monetization agreement with the R-Bridge Healthcare Fund in…
January 15, 2025
Schreiner MediPharm presents innovative cap-lock label for prefilled syringes at Pharmapack
Together with partnering companies SCHOTT Pharma and Körber Pharma, Schreiner MediPharm is going to show how sustainable packaging design can combine waste and cost reduction with user convenience and patient safety.
January 14, 2025
Vetter introduces the next evolution of the V-OVS syringe closure system
Vetter, a globally operating Contract Development and Manufacturing Organization (CDMO), has announced the development and upcoming launch of the new version of its proprietary V-OVS® syringe closure system.
January 13, 2025
Adults in Scotland with rare blood disorder to get access to new oral monotherapy on NHS
Novartis said in a press release Monday that the Scottish Medicines Consortium (SMC) has published advice recommending Fabhalta (iptacopan) for…
January 13, 2025
Cube Biotech and IBA Lifesciences in acquisition deal
Cube Biotech and IBA Lifesciences join forces to advance research and production capabilities for the life science industry by leveraging its complementary strengths to deliver unparalleled solutions in protein purification and stabilization and to enable groundbreaking research in the field of challenging drug targets.
January 13, 2025
Moderna achieves $3B in product sales in 2024
Moderna announced Monday business updates and progress across its pipeline of mRNA medicines, entering 2025 with a focus on a prioritized portfolio addressing respiratory viruses, rare diseases, oncology, and latent and other viruses where there is unmet need, as it achieved $3-3.1B in product sales.
January 13, 2025
Clarivate’s Drugs to Watch report 2025 highlights 11 drugs projected to achieve blockbuster status
Clarivate has released the twelfth annual Drugs to Watch report, its guide to the therapies poised to redefine the future of healthcare, highlighting 11 drugs projected to achieve blockbuster status or revolutionize treatment paradigms within five years.
January 13, 2025
Formycon, Teva team up for Formycon’s biosimilar candidate aflibercept in Europe and Israel
Klinge Biopharma GmbH, the licensee and exclusive global commercialization rights holder for FYB203, Formycon’s biosimilar candidate to Eylea (Aflibercept),has signed a licensing agreement with Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. for the semi-exclusive commercialization of FYB203 in major parts of Europe and Israel. In parallel Formycon has signed an agreement with Teva under which Formycon will supply the finished product.